Research And Markets Neurogenomics And Neurotherapeutic Strategies Study Some New Directions In Pl



H Research And Markets: Neurogenomics And Neurotherapeutic Strategies: Study Some New Directions In Platforms, Targets, And Therapeutic Approaches   

  
Research And Markets: Neurogenomics And Neurotherapeutic Strategies: Study Some New Directions In Platforms, Targets, And Therapeutic Approaches

Research and Markets (researchandmarkets.com/reports/c11423) has announced the addition of Neurogenomics and Neurotherapeutic Strategies: New Directions in Platforms, Targets, and Therapeutic Approaches to their offering.

(PREWB) January 7, 2005 -- Research and Markets (http://www.researchandmarkets.com/reports/c11423) has announced the addition of Neurogenomics and Neurotherapeutic Strategies: New Directions in Platforms, Targets, and Therapeutic Approaches to their offering.

CNS disorders affect a vast patient population and represent a huge area of unmet therapeutic need. In the United States alone, Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) afflict more than 6.5 million people. Drug discovery efforts for the most prevalent CNS diseases have met with varying success; it is estimated that billions of dollars are spent every year on prescription drug sales, however, many current therapies merely treat the symptoms but do not provide cures.

The complexity of CNS diseases make this area a challenging but potentially very rewarding area for research. Neurogenomics and Neurotherapeutic Strategies: New Directions in Platforms, Targets, and Therapeutic Approaches evaluates drug development efforts in six major CNS diseases:

- Alzheimer's disease
- Parkinson's disease
- Amyotrophic Lateral Sclerosis
- Schizophrenia
- Depression
- Bipolar disorder

This report surveys the numerous R&D efforts under way at companies and institutions around the world, focusing on discovery projects, preclinical studies, and early-stage human trials. It also addresses investigational methods, proposed mechanisms of action, pathways, and targets that research teams are exploring in order to move one step closer to developing effective therapeutics. Novel tools and platforms, including animal models, molecular imaging, and biomarkers, will also be covered.

The contents of this report are as follows:
Chapter 1. Introduction
Chapter 2. Alzheimer's Disease
Chapter 3. Parkinson's Disease
Chapter 4. Amyotrophic Lateral Sclerosis
Chapter 5. Schizophrenia
Chapter 6. Major Depression
Chapter 7. Bipolar Disorder
Chapter 8. Therapeutics in Development

For more information visit http://www.researchandmarkets.com/reports/c11423

Laura Wood
Senior Manager
Research and Markets
e-mail protected from spam bots
Fax: +353 1 4100 980





Research And Markets Neurogenomics And Neurotherapeutic Strategies Study Some New Directions In Pl